Patents by Inventor Howard M. Dintzis

Howard M. Dintzis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
    Patent number: 7083959
    Abstract: The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises: i) preparing a construct comprising at least one discrete antigenically recognizable moiety corresponding to an antigenic determinant of an antigen causing the undesired immune response bound to a pharmacologically acceptable carrier wherein the number of the moieties bound to the carrier and the spacing of the moieties on the carrier are such that the construct does not elicit an immune response to the moieties but does directly compete with the antigen for receptors on an immunocompetent cell that recognizes the determinant, and thereby the construct specifically suppresses the undesired immune response; and ii) administering the construct to the mammal in an amount such that suppression of the undesired immune response is effected. The invention further relates to constructs suitable for use in the above method and to methods of making same.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: August 1, 2006
    Assignee: The Johns Hopkins University
    Inventors: Howard M. Dintzis, Renee Z. Dintzis
  • Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
    Publication number: 20020187156
    Abstract: The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response.
    Type: Application
    Filed: January 9, 2001
    Publication date: December 12, 2002
    Applicant: Johns Hopkins University
    Inventors: Howard M. Dintzis, Renee Z. Dintzis
  • Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry
    Patent number: 6375951
    Abstract: The invention features a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen. The construct is free of high molecular weight immunostimulatory molecules and contains copies of the epitope which bind to a B cell membrane immunoglobulin receptor specific for the epitope but fail to form an imnunon.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: April 23, 2002
    Assignee: Johns Hopkins University
    Inventors: Howard M. Dintzis, Renée Z. Dintzis, James K. Blodgett, John C. Cheronis, Gary Kirschenheuter
  • Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry
    Patent number: 6340460
    Abstract: A method of making a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen by coupling two or more copies of the epitope to a nonimmunogenic soluble carrier to yield a conjugate preparation and removing high molecular weight immunostimulatory molecules.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: January 22, 2002
    Inventors: Howard M. Dintzis, Renee Z. Dintzis
  • Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
    Patent number: 6022544
    Abstract: The invention features a method for reducing an undesired antibody response in a mammal by administering to the mammal a non-immunogenic construct which is free of high molecular weight immunostimulatory molecules. The construct which contains at least two copies of a B cell membrane immunoglobulin receptor epitope bound to a pharmaceutically acceptable non-immunogenic carrier directly binds to B cell membrane immunoglobulin receptors but fails to form an immunon.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: February 8, 2000
    Assignee: The John Hopkins University
    Inventors: Howard M. Dintzis, Renee Z. Dintzis, James K. Blodgett, John C. Cheronis, Gary Kirschenheuter
  • Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
    Patent number: 5370871
    Abstract: The present invention relates to a vaccine derived from a bacterial or virus product that initially comprises a mixture of polymers of varying molecular weights. The vaccine contains an immunogenically effective polymer comprising T-cell-independent antigen as the effective immunizing agent. The vaccine is free of low molecular weight immunosuppressive antigen-containing polymer as a result of processing of the bacterial or virus product mixture.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: December 6, 1994
    Assignee: The Johns Hopkins University
    Inventors: Howard M. Dintzis, Renee Z. Dintzis
  • Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
    Patent number: 5126131
    Abstract: Undesired immune responses are suppressed by administering a nonimmunogenic material which comprises one or more haptens or epitopes corresponding to the antigen which causes the undesired immune response, the number and spacing of the haptens or epitopes being insufficient to trigger an immune response but sufficient to inhibit it. Also disclosed is an improved vaccine from which low molecular weight suppressive polymer has been removed.
    Type: Grant
    Filed: September 21, 1988
    Date of Patent: June 30, 1992
    Assignee: The Johns Hopkins University
    Inventors: Howard M. Dintzis, Renee Z. Dintzis